中国组织工程研究

中国组织工程研究 ›› 2010, Vol. 14 ›› Issue (44): 8315-8319.doi: 10.3969/j.issn.1673-8225.2010.44.036

• 器官移植学术探讨 academic discussion of organ transplantation • 上一篇    下一篇

移植静脉桥的再狭窄及其基因治疗

曹园平，刘季春   

  1. 南昌大学第一附属医院心胸外科，江西省南昌市  330006　
  • 出版日期:2010-10-29 发布日期:2010-10-29
  • 通讯作者: 刘季春，博士，教授，南昌大学第一附属医院心胸外科，江西省南昌市 330006 liujichun999@yahoo.com.cn
  • 作者简介:曹园平★，男，1985年生，江西省新余市人，汉族，南昌大学医学院在读硕士，主要从事心脏外科的手术治疗研究。 cyuanping@21cn.com

Gene therapy for vein graft restenosis

Cao Yuan-ping, Liu Ji-chun   

  1. Department of Cardiothoracic Surgery, First Affiliated Hospital of Nanchang University, Nanchang  330006, Jiangxi Province, China
  • Online:2010-10-29 Published:2010-10-29
  • Contact: Liu Ji-chun, Doctor, Professor, Department of Cardiothoracic Surgery, First Affiliated Hospital, Nanchang University, nanchang 330006, Jiangxi Province, China liujichun999@yahoo.com.cn
  • About author:Cao Yuan-ping★, Studying for master’s degree, Department of Cardiothoracic Surgery, First Affiliated Hospital of Nanchang University, nanchang 330006, Jiangxi Province, China cyuanping@21cn.com

PDF

448

被引次数

7

摘要：

背景：冠状动脉旁路移植后静脉桥的再狭窄和闭塞严重影响了其远期疗效，是目前亟待解决的医学难题。
目的：以治疗基因的选择、载体的选择、转染途径的选择为主线就基因治疗静脉桥再狭窄研究进展进行综述。
方法：以移植静脉，基因，治疗，vein graft，gene，therapy为检索词，检索中国期刊全文数据库(网址http://ckrd.cnki.net) 1995-01/2009-07、PubMed数据库(网址http://www.ncbi.nlm.nih.gov/PubMed)1995-01/2009-07。选取与静脉桥再狭窄基因治疗中关于治疗基因、转染载体及转染途径的相关文献，排除陈旧或重复研究的文献。
结果与结论：静脉桥再狭窄严重影响了冠状动脉旁路移植远期疗效，传统的药物治疗收效甚微，基因治疗可将特异性基因精确地定位转染至血管壁，实现外源基因表达，最大限度地在局部发挥生物学效应，减少全身不良反应，被认为是很有前景的方法。基因治疗静脉桥再狭窄由于其独特的优势，将有广阔发展前景。随着对再狭窄机制研究的深入，安全、高效载体的出现，应用多基因联合治疗、药物治疗和物理方式联合治疗等多途径治疗方法将成为预防静脉桥再狭窄发展方向。
　

关键词: 冠状动脉旁路移植, 移植静脉, 狭窄, 基因, 治疗, 组织移植

Abstract:

BACKGROUND: Vein graft restenosis and occlusion seriously affected postoperative long-term effect of coronary artery bypass grafting, which is the difficult medical problem to be solved at present.
OBJECTIVE: To review the therapeutic gene, vectors and transplanted pathway of gene therapy for vein graft restenosis.
METHODS: The relevant articles between January 1995 and July 2009 were retrieved from PubMed (http://www.ncbi.nlm.nih.gov/PubMed) and database of Chinese knowledge (CNKI http://ckrd.cnki.net) using key words of “vein graft, gene, therapy”, and restricting the language as English and Chinese by computer. Literatures addressing therapeutic gene, vectors and transplanted pathway of gene therapy for vein graft restenosis were included. Old or duplicated studies were excluded.
RESULTS AND CONCLUSION: Vein graft restenosis seriously affected postoperative long-term effect of coronary artery bypass grafting. The traditional drug therapy brings little effect. Gene therapy can precisely target specific gene transfection to vascular wall and achieve the expression of exogenous gene, playing the maximum biological effect in the local, reducing systemic side effects. It is considered as a very promising approach. Gene therapy for vein graft restenosis will be broad prospects for development thank to its unique advantages. With the further study of the mechanism of restenosis and the appearance of safe and efficient vectors, the application of multi-gene therapy, drug therapy and physical therapy combination therapy will be the prevention of vein graft restenosis development.

中图分类号: